NeoSync, Inc., a Boston, MA-based clinical-stage company, completion its $13m Series D financing round.
Backers included Valiance Life Science Investments, as well as its original investor base.
The company intends to use the funds for the planned registration study of NEST® Technology in patients with Treatment Resistant Depression (TRD) and preparation for future commercial release of this novel technology.
Led by Kate Rumrill, President and CEO, NeoSync leverages NEST®, its proprietary technology platform, to develop advanced, non-invasive neuromodulation products for the treatment of Major Depressive Disorder and other diseases of the Central Nervous System (CNS).
NEST® (NeoSync-EEG Synchronized TMS) delivers low energy, alternating magnetic field stimulation in daily 30 minute sessions to gently adjust a depressed brain toward a more normal state. Synchronized TMS (sTMS) used by NEST® is personalized to a patient’s individual alpha brain frequency, as measured by a brief electroencephalogram (EEG) recording.
TMS means transcranial magnetic stimulation.